PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynce, Filipa, Saleh, Mervat, Shajahan-Haq, Ayesha, Gallagher, Christopher, Dilawari, Asma, Hahn, Olwen, Abu-Khalaf, Maysa, Cai, Ling, Pohlmann, Paula, Mohebtash, Mahsa, Kamugisha, Lois, Isaacs, Claudine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042467/
https://www.ncbi.nlm.nih.gov/pubmed/30009277
http://dx.doi.org/10.1016/j.conctc.2018.05.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042467/
https://www.ncbi.nlm.nih.gov/pubmed/30009277
http://dx.doi.org/10.1016/j.conctc.2018.05.012

Ejemplares similares